Literature DB >> 34001525

Early Diagnosis and Screening for Lung Cancer.

Humam Kadara1, Linh M Tran2, Bin Liu2, Anil Vachani3, Shuo Li4, Ansam Sinjab1, Xianghong J Zhou4, Steven M Dubinett2,4,5,6,7, Kostyantyn Krysan2,7.   

Abstract

Cancer interception refers to actively blocking the cancer development process by preventing progression of premalignancy to invasive disease. The rate-limiting steps for effective lung cancer interception are the incomplete understanding of the earliest molecular events associated with lung carcinogenesis, the lack of preclinical models of pulmonary premalignancy, and the challenge of developing highly sensitive and specific methods for early detection. Recent advances in cancer interception are facilitated by developments in next-generation sequencing, computational methodologies, as well as the renewed emphasis in precision medicine and immuno-oncology. This review summarizes the current state of knowledge in the areas of molecular abnormalities in lung cancer continuum, preclinical human models of lung cancer pathogenesis, and the advances in early lung cancer diagnostics.
Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34001525      PMCID: PMC8415293          DOI: 10.1101/cshperspect.a037994

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  6 in total

1.  Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta-analysis update.

Authors:  Xiaoxi Zhou; Xiaoling Lu; Haiyan Wu; Juan Liu; He Huang
Journal:  Thorac Cancer       Date:  2021-11-05       Impact factor: 3.500

2.  Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.

Authors:  Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Monika M Kaczmarek; Kamil Myszczyński; Joanna Kiśluk; Anna Majewska; Anna Michalska-Falkowska; Natalia Kodzik; Joanna Reszeć; Ewa Sierko; Jacek Nikliński
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

3.  Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim-Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer.

Authors:  Shaopu Hu; Mengxue Ge; Shuixiu Zhang; Min Jiang; Kaiwen Hu; Lei Gao
Journal:  Front Oncol       Date:  2022-03-30       Impact factor: 6.244

4.  Circulating mitochondrial DNA as a biomarker for lung cancer screening.

Authors:  Mitchell S von Itzstein; David E Gerber; John D Minna
Journal:  Transl Lung Cancer Res       Date:  2022-08

5.  Correlation Analysis of Computed Tomography Features and Pathological Types of Multifocal Ground-Glass Nodular Lung Adenocarcinoma.

Authors:  Jieli Kou; Xiaofei Gu; Liqing Kang
Journal:  Comput Math Methods Med       Date:  2022-07-26       Impact factor: 2.809

6.  The value of narrow-band imaging bronchoscopy in diagnosing central lung cancer.

Authors:  Juanjuan Zhu; Rui Liu; Xiancheng Wu; Qin Li; Beilei Gong; Yuanbing Shen; Yurong Ou; Wei Li
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.